Anti-BRAF 抗体 (ab85972)
Key features and details
- Rabbit polyclonal to BRAF
- Suitable for: WB, IP, IHC-P
- Reacts with: Human
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-BRAF antibody
BRAF 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to BRAF -
由来種
Rabbit -
アプリケーション
適用あり: WB, IP, IHC-Pmore details -
種交差性
交差種: Human
交差が予測される動物種: Mouse, Rat, Cow, Dog, Chimpanzee, Gorilla -
免疫原
Synthetic peptide corresponding to Human BRAF aa 25-75.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
バッファー
pH: 6.8
Preservative: 0.09% Sodium azide
Constituents: Tris buffered saline, 0.1% BSA -
Concentration information loading...
-
精製度
Immunogen affinity purified -
特記事項(精製)
ab85972 was affinity purified using an epitope specific to B Raf immobilized on solid support. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab85972の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/2000 - 1/10000. Predicted molecular weight: 85 kDa.
|
|
IP |
Use at 2-5 µg/mg of lysate.
|
|
IHC-P |
1/200 - 1/1000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
特記事項 |
---|
WB
1/2000 - 1/10000. Predicted molecular weight: 85 kDa. |
IP
Use at 2-5 µg/mg of lysate. |
IHC-P
1/200 - 1/1000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
ターゲット情報
-
機能
Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. -
組織特異性
Brain and testis. -
関連疾患
Note=Defects in BRAF are found in a wide range of cancers.
Defects in BRAF may be a cause of colorectal cancer (CRC) [MIM:114500].
Defects in BRAF are involved in lung cancer (LNCR) [MIM:211980].
Defects in BRAF are involved in non-Hodgkin lymphoma (NHL) [MIM:605027]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.
Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
Defects in BRAF are the cause of Noonan syndrome type 7 (NS7) [MIM:613706]. Noonan syndrome is a disorder characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.
Defects in BRAF are the cause of LEOPARD syndrome type 3 (LEOPARD3) [MIM:613707]. LEOPARD3 is a disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation. -
配列類似性
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily.
Contains 1 phorbol-ester/DAG-type zinc finger.
Contains 1 protein kinase domain.
Contains 1 RBD (Ras-binding) domain. -
細胞内局在
Nucleus. Cytoplasm. Cell membrane. Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes. - Information by UniProt
-
参照データベース
- Entrez Gene: 673 Human
- Entrez Gene: 109880 Mouse
- Entrez Gene: 114486 Rat
- Omim: 164757 Human
- SwissProt: P15056 Human
- SwissProt: P28028 Mouse
- Unigene: 550061 Human
- Unigene: 245513 Mouse
-
別名
- FLJ95109 antibody
- 94 kDa B raf protein antibody
- B raf 1 antibody
see all
画像
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human prostate carcinoma tissue labelling B Raf with ab85972 at 1/200 (1µg/ml). Detection: DAB.
-
All lanes : Anti-BRAF antibody (ab85972) at 0.04 µg/ml
Lane 1 : HeLa whole cell lysate
at 50 µg
Lane 2 : HeLa whole cell lysate
at 15 µg
Lane 3 : HeLa whole cell lysate
at 5 µg
Lane 4 : 293T whole cell lysate
at 50 µg
Predicted band size: 85 kDa
Observed band size: 95 kDa why is the actual band size different from the predicted?
Additional bands at: 238 kDa, 60 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 3 minutes -
Detection of B Raf by Western Blot of Immunprecipitate.
ab85972 at 1µg/ml staining B Raf in HeLa whole cell lysate immunoprecipitated using ab85972 at 3µg/mg lysate (1 mg/IP; 20% of IP loaded/lane). Detection: Chemiluminescence with exposure time of 10 seconds.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (2)
ab85972 は 2 報の論文で使用されています。
- Kaneko N et al. Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell 183:143-157.e13 (2020). PubMed: 32877699
- Yin C et al. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell 176:1113-1127.e16 (2019). PubMed: 30712867